Replies to post #1806 on SmurfVA's Random Picks

[SmurfVA]

LXRX - Am sucking it up on this one and wait out. Lexicon's LX4211 is a first-in-class dual inhibitor of SGLT1 and SGLT2. The allure of SGLT2 inhibitors such as Invokana and Farxiga is that they lead to glycemic balance while also lowering blood pressure and inducing weight loss, which is a notable improvement, in my opinion, over weight-neutral DPP-4 inhibitors. Based on its top-line phase 2 data, LX4211 has also delivered a similar blood pressure and weight loss response while aiding glycemic balance. If LX4211 delivers more impressive clinical results than either Invokana or Farxiga in lessening A1C levels, it's quite possible Lexicon shares could soar.

Ref. http://www.fool.com/investing/general/2014/02/28/3-biotech-companies-that-could-be-the-next-interce.aspx